Open AccessData on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
Author(s) -
Л. А. Суплотова,
Суплотова Людмила Александровна,
Н. В. Плотников,
Плотников Николай Валерьевич,
Natal'ya Valer'yanovna Romanova,
Романова Наталья Валерьяновна,
Лариса Николаевна Бельчикова,
Бельчикова Лариса Николаевна,
E.V. Khieva,
Хиева Екатерина Викторовна,
Marina Shestakova,
Шестакова Марина Владимировна
Publication year - 2015
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/dm7695
Subject(s) - medicine , insulin degludec , insulin , postprandial , diabetes mellitus , observational study , hypoglycemia , type 2 diabetes , type 2 diabetes mellitus , endocrinology , insulin glargine
Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patients (mean age: 57.2 years, range: 54.4–61.5 years), who were inadequately controlled on maximum tolerated doses of oral antidiabetic drugs (OADs) and in whom baseline insulin therapy with ultra-long-acting insulin degludec was initiated. The duration of treatment was 6 months. The list of procedures met the ‘Standard of primary medical care in non-insulin-dependent diabetes mellitus’, as approved by the Ministry of Health of the Russian Federation (12.28.2012 №1581-n). Quality of life was assessed using the SF-36 questionnaire. All patients provided written consent before participating in the study.Results: In the outpatient setting, insulin degludec was well tolerated by all the patients. During the observational period, there were no events of symptomatic hypoglycaemia confirmed by self-measured plasma glucose (blood glucose level 3.9 mmol/l). At the end of the observational period, HbA1c, fasting plasma glucose level (FPG) and postprandial (2 h after a meal) plasma glucose level (PPG) had decreased. Despite the fact that most of the patients had poor baseline glycaemic control, after 6 months of degludec therapy, 45% of the participants achieved a target HbA1c of 7.0%, and 45% achieved a target HbA1c of 8.0%. Improved glycaemic control was associated with increased quality of life scores on both physical and mental health components.Conclusion: In this primary health care clinical observational study, the initiation of insulin degludec in type 2 diabetes patients with poor glycaemic control on OADs was associated with the achievement of effective glycaemic control. In addition, it had a good safety profile, and it improved quality of life scores and adherence to the treatment.